ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health. In addition, the company provides contract manufacturing services of OTC healthcare and dietary supplements products. It markets its products through national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone215-345-0919
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$13.13 million
Profitability
Miscellaneous
Employees47
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable
ProPhase Labs (NASDAQ:PRPH) Frequently Asked Questions
What is ProPhase Labs' stock symbol?
ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH."
How often does ProPhase Labs pay dividends? What is the dividend yield for ProPhase Labs?
ProPhase Labs announced a dividend on Wednesday, November 20th. Investors of record on Tuesday, December 3rd will be paid a dividend of $0.25 per share on Thursday, December 12th. The ex-dividend date is Monday, December 2nd. View ProPhase Labs' Dividend History.
How were ProPhase Labs' earnings last quarter?
ProPhase Labs Inc (NASDAQ:PRPH) posted its quarterly earnings data on Monday, August, 12th. The company reported ($0.11) EPS for the quarter. The firm had revenue of $1.65 million for the quarter. ProPhase Labs had a negative net margin of 29.05% and a negative return on equity of 20.48%. View ProPhase Labs' Earnings History.
When is ProPhase Labs' next earnings date?
Has ProPhase Labs been receiving favorable news coverage?
Media headlines about PRPH stock have trended very negative this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ProPhase Labs earned a coverage optimism score of -3.0 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for ProPhase Labs.
Are investors shorting ProPhase Labs?
ProPhase Labs saw a decrease in short interest during the month of January. As of January 15th, there was short interest totalling 7,800 shares, a decrease of 29.1% from the December 31st total of 11,000 shares. Based on an average trading volume of 3,000 shares, the short-interest ratio is currently 2.6 days. Currently, 0.1% of the company's shares are sold short. View ProPhase Labs' Current Options Chain.
Who are some of ProPhase Labs' key competitors?
Some companies that are related to ProPhase Labs include CV Sciences (CVSI), Oncolytics Biotech (ONCY), Infinity Pharmaceuticals (INFI), Catalyst Biosciences (CBIO), Elite Pharmaceuticals (ELTP), Stealth BioTherapeutics (MITO), Onconova Therapeutics (ONTX), Eyenovia (EYEN), Chembio Diagnostics (CEMI), Trevena (TRVN), Cumberland Pharmaceuticals (CPIX), CTI BioPharma (CTIC), Entasis Therapeutics (ETTX), DiaMedica Therapeutics (DMAC) and CNS Pharmaceuticals (CNSP).
What other stocks do shareholders of ProPhase Labs own?
Who are ProPhase Labs' key executives?
ProPhase Labs' management team includes the folowing people:
- Mr. Ted William Karkus, Chairman & CEO (Age 60)
- Ms. Monica Brady, CFO & Chief Accounting Officer (Age 42)
How do I buy shares of ProPhase Labs?
Shares of PRPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is ProPhase Labs' stock price today?
One share of PRPH stock can currently be purchased for approximately $1.75.
How big of a company is ProPhase Labs?
What is ProPhase Labs' official website?
How can I contact ProPhase Labs?
ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The company can be reached via phone at 215-345-0919 or via email at [email protected]
MarketBeat Community Rating for ProPhase Labs (NASDAQ PRPH)
MarketBeat's community ratings are surveys of what our community members think about ProPhase Labs and other stocks. Vote "Outperform" if you believe PRPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
